¼ÐÃD: ÂåÃĪÑ
chousirbuy
¦P¾Ç




UID 71566
ºëµØ 0
¿n¤À 0
©«¤l 136
¾\ŪÅv­­ 99
µù¥U 2017-12-30
¥Î¤áµù¥U¤Ñ¼Æ 2280
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1963

114.32.128.158
µoªí©ó 2018-10-16 20:46  ¸ê®Æ ¨p¤H°T®§ 
¤µ¤Ñ¦bµØº¸µó¤é³ø¬Ý¨ìABBVIEªºHumiraÃÄ, ¼Ú¬wªº±M§Q¨ì´Á, ¨ä¥LªºÃļt¥i¥H±À¥X¾Ç¦WÃÄ
¦ý¬OHumira¦b¬ü°ê¨ä¹ê2016¦~±M§Q´N¨ì´Á¤F, ¦ý¨ä¥LÃļt¿ð¿ðµLªk±À¥X²£«~

³Ì¥D­nªº­ì¦]¬OAbbVie¥Î¤F¤W¦Ê­Ó±M§Q«Ø¥ß°_¤@¹D±M§QÀð
´N¥Ø«e¥´¹Lªº©x¥q¨Ó¬Ý, ©M¨ä©M¸Ñªº¼t°Ó¥²»Ý­n2023¦~¤~¯à°÷¤W¥«
¤v©M¸Ñ¼t°Ó¦³Amgen, ¤T¬PBioepis, Mylan©M¿ÕµØ¤½¥q
¥¼©M¸Ñªº¼t°Ó¦³Boehringer Ingelheim¡A¥¦­p¹º¦b2023¦~¤§«e¦b¬ü°ê±À¥X


¥Ø«e¬Ý¨Ó¡AAbbVie¾Ö¦³¤@ºØÃĪ«ªºÃbÂ_Åv
¦Ó¥B±q15¦~«e±À¥X¥H¨Ó»ù®æÁ`¦@º¦»ù¶W¹L6¸U¬ü¤¸
¥h¦~¥þ¬ü°ê¾P°âª÷ÃB¶W¹L120»õ¬ü¤¸¡C



³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

140.114.74.23
µoªí©ó 2018-10-20 14:03  ¸ê®Æ ¨p¤H°T®§ 
¤pªL»sÃÄ Kobayashi Pharmaceutical Company, Limited (¤éªÑ 4967)  (¤é¥Î«~,»sÃÄ)

https://www.kobayashi.co.jp/english/company/index.html

https://zh.wikipedia.org/wiki/%E5%B0%8F%E6%9E%97%E8%A3%BD%E8%97%A5


¤pªL»sÃĪѥ÷¦³­­¤½¥q¡A²ºÙ¤pªL»sÃÄ¡]­^»y¡GKobayashi Pharmaceutical Company, Limited¡A¤é»y¡G¤pªL»s薬®è¦¡会ªÀ¡AªFÃÒ1³¡¡G4967¡^¡A¦b1886¦~³Ð¥ß·í®É¦W¬°¡u¤pªL²±¤j°ó¡v¡A·í®ÉÁ`³¡¦ì©ó¦W¥j«Î¡A¦Ó³Ð¿ì¤H¬°¤pªL©¾§L½Ã¡A·í®É¸gÀç¥X°âÂø³f©±¡B¤Æ§©«~¤Î¬v°sµ¥¡C


²{®É¥D­n·~°È¨Æ·~(¦U¦¡¦U¼ËÂåÃÄ«~¡BªÚ­»¾¯¡B½Ã¥Í¥Î«~¡B¤é¥Î¥²»Ý«~¡B«O°·²£«~µ¥)¤Î¨ÑÀ³ÂåÀø¾÷¾¹ªº¾P°â¨Æ·~[1]¡A²{®ÉÁ`³¡¦ì©ó¤j¨Á©²¤j¨Á¥«¤¤¥¡°Ï¹D­×Ëm¥|¤B¥Ø4µf10¸¹KDX¤pªL¹D­×Ëm¤j¼Ó¡C¸³¨Æªø¤Î­º®u°õ¦æ©x¬°¤pªL¤@¶®¡C
¦ÓªÑ¥÷¦b1999¦~4¤ë20¤é©ó¤j¨ÁÃÒ¨é¥æ©ö©Ò¡]«á¤w¸Ñ´²¡^²Ä¤G³¡¤W¥«¡A¦Ó¦b2000¦~8¤ë22¤é©óªF¨ÊÃÒ¨é¥æ©ö©Ò©M¤j¨ÁÃÒ¨é¥æ©ö©Ò¡]«á¤w¸Ñ´²¡^²Ä¤@³¡¤W¥«¡C


2018¦~3¤ë29¤é¤pªL»sÃĤ½¥q¡A±N¦¬Áʤ@®a¤¤°êÂåÃÄ«~¥Í²£¾P°â¤½¥q¦¿Ä¬¤¤¤¦»sÃĦ³­­¤½¥q¡A¤µ«á±N¦b·í¦a¥Í²£©M¾P°â¦b¤¤°ê³X¤é¹C«È¤¤¤H®ð»á°ªªº®øª¢Âíµh¾¯¡u¦w¬üÅS¡vµ¥ÂåÃÄ«~¡C¦¬Áʪ÷ÃB¥¼¹ï¥~¤½¥¬

³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

140.114.74.23
µoªí©ó 2018-10-20 14:06  ¸ê®Æ ¨p¤H°T®§ 
Kyowa Hakko Kirin Co., Ltd. (¨ó©M発»ÃÇ©ÇæÇï®è¦¡会ªÀ) (¤éªÑ 4151) »sÃĥͪ«¬ì§Þ

http://www.kyowa-kirin.com/products/index.html


http://www.kyowa-kirin.com/about_us/overview/index.html



https://en.wikipedia.org/wiki/Kyowa_Hakko_Kirin

Kyowa Hakko Kirin Co., Ltd. (¨ó©M発»ÃÇ©ÇæÇï®è¦¡会ªÀ Kyōwa Hakkō Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.[4][5]


Kyowa Hakko Kirin Co., Ltd.


Type
Traded asIndustryFoundedHeadquartersKey people
ProductsRevenueNet income
Number of employees
ParentSubsidiariesWebsite
Public KK
TYO: 4151
FWB: KY4
Nikkei 225 Component

July 1, 1949
Ohtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100-8185, Japan
Nobuo Hanai, (CEO and President)

$ 3.548 billion USD (FY 2013)
(¥ 340.61 billion JPY) (FY 2013)
$ 31.32 million USD (FY 2013)
(¥ 30.07 billion JPY) (FY 2013)
7,532 (consolidated) (as of December 31, 2017)
Kirin Holdings Company, Limited
47 (33 in Japan and 14 overseas countries)
Official website
Footnotes / references
[1][2][3]


³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

140.114.74.23
µoªí©ó 2018-10-20 14:07  ¸ê®Æ ¨p¤H°T®§ 
¤j¤é¥»¦í¤Í»s薬®è¦¡会ªÀ  Sumitomo Dainippon Pharma Co., Ltd. (¤éªÑ 4506)  »sÃÄ

https://www.ds-pharma.co.jp/

https://zh.wikipedia.org/wiki/%E5%A4%A7%E6%97%A5%E6%9C%AC%E4%BD%8F%E5%8F%8B%E8%A3%BD%E8%97%A5


¤j¤é¥»¦í¤Í»sÃĪѥ÷¦³­­¤½¥q¡]¤é»y¡G¤j¤é¥»¦í¤Í»s薬®è¦¡会ªÀ¡B­^»y¡GSumitomo Dainippon Pharma Co., Ltd.¡^¬O¤é¥»¤@®a»sÃĤ½¥q¡C¨ä¬°¦í¤Í¤Æ¾Ç©ÒÄÝ¡C«e¨­¬°1897¦~¦¨¥ßªº¤j¨Á»s薬®è¦¡·|ªÀ»P1984¦~¦¨¥ßªº¦í¤Í»sÃĮ覡·|ªÀ¡C

¤j¤é¥»¦í¤Í»sÃĮ覡·|ªÀ


­ì¤å¦WºÙ¤½¥qÃþ«¬¦¨¥ß¥Nªí¤Hª«Á`³¡²£«~Àç·~ÃB­û¤u¤H¼Æ¹ê¦¬¸ê¥»ÃBµ²ºâ´Á¥D­nªÑªF¥D­n¤l¤½¥qºô¯¸

Sumitomo Dainippon Pharma Co., Ltd.
[/url]
¤j¤é¥»¦í¤Í»s薬®è¦¡会ªÀ
®è¦¡·|ªÀ
¤j¤é¥»»sÃÄ1897¦~5¤ë14¤é
¦í¤Í»sÃÄ1984¦~2¤ë6¤é
¦X¨Ö2005¦~10¤ë1¤é
¥Nªí¨ú½l§Ð·|ªø®cªZ°·¦¸­¦
¥Nªí¨ú½l§ÐªÀªø¦h¥Ð¥¿¥@
¤j¨Á©²¤j¨Á¥«¤¤¥¡°Ï¹D­×Ëm¤G¤B¥Ø6µf8¸¹
Âå薬«~¡BÁ{§ÉÀË査ÃÄ¡BÂåÀø¾÷¾¹¡B°Êª«¥ÎÂå薬«~
­¹«~²K¥[ª«¡B¤u·~薬«~¡B¨ä¥L¤Æ¾Ç»s«~ªº»s³y
3,0637.00»õ¤é¶ê¡]2010¦~¡A¥þÅéÀ禬¡^
7,407¦W¡]2010¦~3¤ë31¤é²{¦b¡^
224»õ円¡]2009¦~3¤ë¥½²{¦b¡^
¨C¦~3¤ë31¤é
¦í¤Í¤Æ¾Ç50.12%
稲畑産·~6.86%
¡]2010¦~3¤ë31¤é²{¦b¡^
DSP¤­¨óÇÑÆãÇÅ¡®Ç­ÇÛǧÇç®è¦¡·|ªÀ
http://www.ds-pharma.co.jp/

³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

140.114.74.23
µoªí©ó 2018-10-20 14:08  ¸ê®Æ ¨p¤H°T®§ 
KAKEN PHARMACEUTICAL CO.,LTD. (¤éªÑ 4521) »sÃÄ



http://www.kaken.co.jp/english/business/index.html


http://www.kaken.co.jp/english/about_kaken/profile.html



Kaken Pharmaceutical Co., Ltd. (KAKEN) is a specialty pharmaceutical company in Japan with strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics, dermatology and surgery.

The origins of KAKEN can be traced back to the Institute of Physical and Chemical Research (Riken), which was established in 1917. In 1948, Riken reorganized into Kagaku-Kenkyusho, which is the precursor of KAKEN, and started its pharmaceutical business by developing a new way to manufacture penicillin utilizing Riken¡¦ proprietary technologies.

KAKEN has since broadened the scope of its business activities to include the production and marketing of pharmaceuticals such as streptomycin, an anti-tuberculosis drug, and various antifungal agents. In recent years, KAKEN concentrates its R&D resources in inflammation/immunology (dermatitis, rheumatoid arthritis and osteoarthritis), pain relief and fungal infection areas.

KAKEN¡¦s ongoing quest is to bring smiles and happiness to as many people as possible. For this purpose, KAKEN strives to improve the quality of life of patients through the development and distribution of superior pharmaceuticals.

³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

140.114.74.23
µoªí©ó 2018-10-20 14:09  ¸ê®Æ ¨p¤H°T®§ 
Hisamitsu Pharmaceutical Co., Inc. ¤[¥ú»sÃĮ覡·|ªÀ (¤éªÑ 4530)  »sÃÄ

http://www.hisamitsu.co.jp/healthcare/


https://zh.wikipedia.org/wiki/%E4%B9%85%E5%85%89%E8%A3%BD%E8%97%A5

¤[¥ú»sÃĮ覡·|ªÀ¡]¤é»y¡G¤[¥ú»s薬®è¦¡会ªÀ¡B­^»y¡GHisamitsu Pharmaceutical Co., Inc.¡^¬O¤@®a¤é¥»ªº»sÃĤ½¥q¡AÁ`³¡¦ì©ó¦õ¶P¿¤³¾Ñᥫ¤ÎªF¨Ê³£¡C©ó1847¦~¡]¥°¤Æ4¦~¡^¦¨¥ßªº¸Ó¤½¥q¡A«e¨­­ì¦W¤pªQ«Î¡A¥H¥Í²£¨Ï¥Î¼»¶©¤Ú´µ¡]¤é»y¡GDZÇéÇïÇÍǵ¡A­^»y¡GSalonpas¡^§@¬°°Ó¼Ð¦Wªº»Äµh¶K¥¬»P¨ä­l¥ÍÃÄ«~¦Óª¾¦W¡C


¤[¥ú»sÃĦb¤E¦{Á`³¡©Ò¦bªº³¾Ñᥫ»P栃¤ì¿¤¦t³£®c¥«¦U³]¦³¤@®y¥Í²£¤u¼t¡A©ó¤é¥»°ê¤º¶±¥Î1,400¦W¥H¤Wªº­û¤u¡C

¤[¥ú»sÃĮ覡·|ªÀ
¤½¥qÃþ«¬¦¨¥ß¥Nªí¤Hª«Á`³¡²£·~Àç·~ÃB­û¤u¤H¼Æ¥D­n¤l¤½¥qºô¯¸
Hisamitsu Pharmaceutical Co., Inc.
¤W¥«¤½¥q
ªFÃÒ1³¡¡G4530
¦WÃÒ1³¡¡G4530
1847¦~
¤¤冨³Õ¶©¡]¦æ¬FÁ`µô¤ÎªÀªø¡^
¤é¥»¦õ¶P¿¤³¾Ñᥫ¥Ð¥N¤j©xËm408
»sÃÄ¡BÂåÀø½Ã¥Í
¡¶1,240»õ¤é¶ê¡]2009¦~2¤ë¡^
1,428¤H¡]2012¦~2¤ë¡^
Hisamitsu America Inc.
Noven Pharmaceuticals, Inc.
Hisamitsu Farmaceutica do Brasil Ltda.
¤[¥ú»sÃħ޳N¿Ô¸ß¡]¥_¨Ê¡^¦³­­¤½¥q
Hisamitsu Vietnam Pharmaceutical Co., Ltd.
PT.Hisamitsu Pharma Indonesia
Hisamitsu UK Limited
www.hisamitsu.co.jp

³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

140.114.74.23
µoªí©ó 2018-10-20 14:10  ¸ê®Æ ¨p¤H°T®§ 
TSUMURA & CO. (¤éªÑ 4540) »sÃÄ (º~¤è»s¾¯,ÂåÀø«~)

http://www.tsumura.co.jp/

http://www.tsumura.co.jp/english/kampo/

³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

140.114.74.23
µoªí©ó 2018-10-20 14:10  ¸ê®Æ ¨p¤H°T®§ 
³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

140.114.74.23
µoªí©ó 2018-10-20 14:11  ¸ê®Æ ¨p¤H°T®§ 
²Ä¤@¤T¦@  DAIICHI SANKYO COMPANY,LIMITED (¤éªÑ 4568) »sÃÄ


https://en.wikipedia.org/wiki/Daiichi_Sankyo

https://www.daiichisankyo.com.tw/


https://www.daiichisankyo.com.tw/about/index01.asp



Daiichi Sankyo Company, Limited (²Ä¤@¤T¦@®è¦¡会ªÀ Daiichi Sankyō Kabushiki-kaisha) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.


Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo, Company, Limited and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in Parsippany, New Jersey.
Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.


Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).


Daiichi Sankyo Company, Limited


Type
Traded asIndustryPredecessorFoundedHeadquartersKey people
ProductsRevenueNet income
Number of employees
Website
Public KK
TYO: 4568
TOPIX Large 70 Component
TOPIX 100 Component
Nikkei 225 Component
Pharmaceutical
  • Daiichi Pharmaceutical Company
  • Sankyo Company

Tokyo, Japan (2005) (by merger)
Daiichi Sankyo Building A/B 3-5-1, Nihonbashi-honcho, Chūō-ku, Tokyo 103-8426, Japan
Joji Nakayama, (CEO and President)

$ 12.006 billion USD (FY2012)
(¥ 997.852 billion JPY) (FY 2012)
$ 0.801 billion USD (FY2012)
(¥ 66.621 billion JPY) (FY 2012)
32,229 (as of December 2013)
http://www.daiichisankyo.com
Footnotes / references
[1][2]

³»³¡
½«ÂÅ
¦P¾Ç




UID 69417
ºëµØ 0
¿n¤À 0
©«¤l 221
¾\ŪÅv­­ 99
µù¥U 2017-10-30
¥Î¤áµù¥U¤Ñ¼Æ 2342
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1572

219.85.93.231
µoªí©ó 2018-10-21 20:46  ¸ê®Æ ¨p¤H°T®§ 
³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

120.107.160.32
µoªí©ó 2018-10-27 12:28  ¸ê®Æ ¨p¤H°T®§ 
«ô¦ÕªÑ¥÷¤½¥q¡]Bayer AG ) ( ¼wªÑ BAYN )

https://www.bayer.com/

https://zh.wikipedia.org/wiki/%E6%8B%9C%E8%80%B3



«ô¦ÕªÑ¥÷¤½¥q¡]Bayer AG /ˈbaÈþər/; ¼w»yµo­µ¡G[ˈbaÈþ̯Èö]¡^¬O¤@®a¼w°ê»sÃĤΤƤu¸ó°ê¶°¹Î¡]±dªö®¦¡^¡A¼w°êªÑ²¼«ü¼ÆDAXªº¦¨¤À¤½¥q¡A¥@¬É500±j¤§¤@¡C¨äÁ`³¡¦ì©ó¼w°ê°Ç¨U®w´Ë¡A³ÌµÛ¦Wªº²£«~¬Oªü¥q¤ÇªL¡A³o¤]¬O¸Ó¤½¥q³Ì¦­¶}µoªº²£«~¡C¬ü°ê¥Íª«§Þ³N¤½¥q©s¤s³£¬°ºX¤U³¡ªù¡C




«ô¦ÕªÑ¥÷¤½¥q
¤½¥qÃþ«¬ªÑ²¼¥N¸¹¦¨¥ß¥Nªí¤Hª«Á`³¡²£·~²£«~Àç·~ÃBµ|«e¬Õ¾lµ|«á¬Õ¾lÁ`¸ê²£¸ê²£²b­È­û¤u¤H¼Æºô¯¸
(Xetra¨t²Î¥æ©öªº)¤½²³¤½¥q
FWB: BAYN
1863¦~8¤ë1¤é¡A¥Ñ´I¾¤¼w¨½§Æ¡E«ô¦Õ¡]Friedrich Bayer¡^»P¬ù¿«¡E´I¾¤¼w¨½§Æ¡E«Â´µ¦Ò¯S¡]Johann Friedrich Weskott¡^«Ø¥ß
Werner Wenning (CEO)
Manfred Schneider (ºÊ²z·|¥D®u)
¼w°ê°Ç¨U®w´Ë
»sÃÄ¡B¹A·~¡B¥Íª«§Þ³N¡B¤Æ¾Ç¤u·~
°£¯ó¾¯¡B¹AÃÄ¡B½\ª«ºØ¤l¡BÂåÀøÃÄ«~
¡¶ £á463.24»õ¡]2015¡^[1]
¡¶ £á62.50»õ¡]2015¡^[1]
¡¶ £á41.10»õ¡]2015¡^[1]
¡¶ £á739.17»õ¡]2015¡^[2]
¡¶ £á254.45»õ¡]2015¦~¦~¥½¡^[2]
116,800 (FTE, 2015)[1]
http://www.bayer.com/

³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

120.107.160.32
µoªí©ó 2018-10-27 12:29  ¸ê®Æ ¨p¤H°T®§ 
«ôº¸´µ¹D¤Ò Beiersdorf AG (¼wªÑ BEI)

https://www.beiersdorf.com/about-us/overview

https://zh.wikipedia.org/wiki/%E6%8B%9C%E5%B0%94%E6%96%AF%E9%81%93%E5%A4%AB


«ôº¸´µ¹D¤ÒªÑ¥÷¤½¥q¡]¼w»y¡GBeiersdorf AG¡^¬O¤@®a¤½¶}¤W¥«ªº±q¨Æ°ê»Ú¤Æ¸gÀ窺»s¦¨«~±dªö®¦¡AÁ`³¡³]©ó¼w°êº~³ù¡C¨ä¦h¼ÆªÑ¥÷¥Ñ»®¯ý®a±Ú¡]Familie Herz¡^©Ò±±ªÑªº°¨§J¦è®¦ºû´µ¯SªÑ¥÷¤½¥q«ù¦³¡C


«ôº¸´µ¹D¤ÒªÑ¥÷¤½¥q

¤½¥qÃþ«¬ªÑ²¼¥N¸¹¦¨¥ß¥Nªí¤Hª«Á`³¡²£·~²£«~Àç·~ÃBµ|«e¬Õ¾lµ|«á¬Õ¾lÁ`¸ê²£¸ê²£²b­È­û¤u¤H¼Æºô¯¸
Beiersdorf AG
ªÑ¥÷¤½¥q
FWB: BEI
1882¦~3¤ë28¤é
¦«°¨´µ-¥»¼w¡P¦j´µ (°õ¦æªø)
¼w°êº~³ù
¤Æ¤u¡BÂåÃÄ
­Ó¤HÅ@²z²£«~
£á 60.4 »õ¼Ú¤¸ (2012)[1]
£á 735 ¦Ê¸U (2012)[1]
£á 477 ¦Ê¸U (2012 ¦~¥½)[1]
£á 55.75 »õ (2012 ¦~¥½)[1]
£á 32.87 »õ (2012 ¦~¥½)[1]
16,605 (2012 ¦~¥½)[1]
Beiersdorf.com
³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

120.107.160.32
µoªí©ó 2018-10-27 12:38  ¸ê®Æ ¨p¤H°T®§ 
¶O´Ë¤×´µ Fresenius SE & Co. KGaA (¼wªÑ FRE)   

¼w°ê³Ì¤jªº»sÃÄÂåÀøªA°È¥ø·~©M¨p¥ßÂå°|¹BÀç°Ó

https://www.fresenius.com/

https://zh.wikipedia.org/wiki/%E8%B4%B9%E6%A3%AE%E5%B0%A4%E6%96%AF


¶O´Ë¤×´µ¼Ú¬wªÑ¥÷¨â¦X¤½¥q¡]¼w»y¡GFresenius SE & Co. KGaA¡^¬O¤@¶¡Á`³¡¦ì©ó¶Â´Ë¦{¤Ú¯S¬x³ùªº¼w°êÂåÀø§Þ³N©M«O°·¤½¥q¡C¸Ó¤½¥q¬O¡m°]´I¡nÂø»xµû¥Xªº¥@¬É500±j¤§¤@¡A¤]¬O¼w°ê³Ì¤jªº»sÃÄÂåÀøªA°È¥ø·~©M¨p¥ßÂå°|¹BÀç°Ó¡A©ó2007¦~7¤ë13¤é¥¿¦¡«Ø¨î¬°¼Ú¬wªÑ¥÷¤½¥q[2]¡A¨Ã©ó2009¦~3¤ë23¤é¦¨¬°¼w°êDAX«ü¼Æªº¦¨¤À¤½¥q[3]¡C¦¹¥~¡A¶O´Ë¤×´µÁÙ«ù¦³³zªR¥ø·~¶O´Ë¤×´µÂåÀøªº¦h¼ÆªÑÅv[4]¡C



¶O´Ë¤×´µ¼Ú¬wªÑ¥÷¨â¦X¤½¥q

¤½¥qÃþ«¬¦¨¥ß³Ð¿ì¤H¥Nªí¤Hª«Á`³¡²£·~²£«~Àç·~ÃBµ|«e¬Õ¾lµ|«á¬Õ¾lÁ`¸ê²£­û¤u¤H¼Æºô¯¸
Fresenius SE & Co. KGaA
¼Ú¬wªÑ¥÷¤½¥q¤Î¨â¦X¤½¥q¡]FWB: FRE¡^
1912¦~
·R¼wµØ¡P¶O´Ë¤×´µ
¡]Eduard Fresenius¡^
¯Qº¸¤Ò¡P°¨§J¡P´µ©`¼w¡]CEO¡^
¡]Ulf Mark Schneider¡^
¼w°ê¤Ú¯S¬x³ù
ÂåÀø§Þ³N
³zªR¡BÀR¯ßª`®g¡BÃĪ«ªvÀø¡B
Âå°|
£á159.7»õ¡]2010¦~¡^[1]
£á24.18»õ ¡]2010¦~¡^[1]
£á6.22»õ ¡]2010¦~¡^[1]
£á235.8»õ¡]2010¦~¡^[1]
137550 ¡]2010¦~¡^[1]
www.fresenius.se
³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

120.107.160.32
µoªí©ó 2018-10-27 12:45  ¸ê®Æ ¨p¤H°T®§ 
Àq§J¶°¹Î¡]Merck KGaA¡^(¼wªÑ MRK)

https://www.merckgroup.com/en

https://zh.wikipedia.org/wiki/%E9%BB%98%E5%85%8B%E9%9B%86%E5%9C%98


Àq§J¦¨¥ß©ó1668¦~¡A¥ì°Ò¯Ã¡PÀq§J³Ð³]¥þ¥@¬É²Ä¤@®aÃħ½¡A¤µ¤éªºÀq§J¬°¥þ¥@¬É¾ú¥v³Ì±y¤[ªº¤Æ¤u»sÃĤ½¥q¡C

Àq§J¶°¹Î¡]Merck KGaA¡^³Ð«Ø©ó1668¦~¡A¾Ö¦³¬ù350¦~¾ú¥v¡AÁ`³¡¦ì©ó¼w°ê¹F©i¬I¶ð¯S¥«¡]Darmstadt¡^¡A¸Ó¶°¹Î¥D­n­P¤O©ó³Ð·s«¬»sÃÄ¡B¥Í©R¬ì¾Ç¥H¤Î«eªu¥\¯à§÷®Æ§Þ³N¡CÀq§J¶°¹Î©l²×¥H§Þ³N¬°ÅX°Ê¤O¡A¬°±wªÌ©M«È¤á³Ð³y»ù­È¡CºI¤î2012¦~¡AÀq§J¦b¥þ²y67­Ó°ê®a©M¦a°Ï¾Ö¦³154­Ó¤À¤ä¾÷ºc¡A¥H¤Î38,000¦W­û¤u¹O¡CÀq§J¦b¬ü°ê©M¥[®³¤j¨Ï¥ÎEMD«~µP¡AEMD¥Nªí¹F©i¬I¶ð¯S¥ì°Ò¯Ãº¸Àq§J¡A·N§YEmanuel Merck Darmstadt¡C

Àq§J­P¤O©ó¦b¥þ²y½d³ò¤º¬°±wªÌ©M«È¤á´£¨Ñ³Ì¨Îªº¸Ñ¨M¤è®×¡C¦b¤¤°ê¡AÀq§J¥D­n±q¨Æ»sÃÄ¡B¥Í©R¬ì¾Ç©M¤Æ¤u·~°È¡A¨Ã¬°«È¤á´£¨Ñ¼sªxªº²£«~¡G±q³Ð·s«¬ªº³B¤èÃþÃÄ«~¡B«D³B¤èÃþÃÄ«~¨ì¥Í©R¬ì¾Ç»â°ìªº¸Ñ¨M¤è®×¡A¤u·~¥Î³~ªº®ÄªGÃC®Æ©M¤Æ¾Ç«~¡CÀq§Jªº·~°È¥D­n¤À¬°¥|¤j¤À¤ä¡GÀq§J³·Äõ¿Õ·~°È¤À¤ä¡B®ø¶OªÌ«O°··~°È¤À¤ä¡BÀq§J±K²z³Õ·~°È¤À¤ä¡B¥\¯à©Ê§÷®Æ·~°È¤À¤ä¡C

Àq§J¶°¹Î¥þ²y·~°È¥Ñ¦ì©ó¼w°ê¹F©i¬I¶ð¯S¥«ªºÁ`¤½¥q²ÎÄwºÞ²z¡CÀq§J¶°¹Î©ó1995¦~¦bªkÄõ§JºÖÃÒ¥æ©Ò¤W¥«¡A©ó2007¦~³Q¦C¤JDAX®«ü¼Æ¤½¥q¡CÀq§J¶°¹ÎÁ`¸ê¥»¬ù70%¥ÑÀq§J®a±Ú³q¹L E. Merck OHG ¤½¥q©Ò«ù¦³¡A¨ä¾l30% ¥Ñ¦Û¥ÑªÑªF©Ò«ù¦³¡C Àq§J¶°¹Î2012¦~ªºÁ`¦¬¤J¬°111.73»õ¼Ú¤¸¡A¸û2011¦~¼W´T8.7%¡A¨ä¤¤¾P°âÃB¬°107.41»õ¼Ú¤¸¡A¸û2011¦~¼W´T8.4%¡F¦b¬ã¨s»P¶}µo¤W§ë¸ê15.11»õ¼Ú¤¸¡A¸û2011¦~°ò¥»«ù¥­¡C¦bÁ`¾P°âÃB¤¤¡AÀq§J³·Äõ¿Õ©Ò¥e¤ñ­«³Ì¤j¡A¬°56%¡AÀq§J±K²z³Õ¬°24%¡A¥\¯à©Ê§÷®Æ·~°È¬°16%¡A®ø¶OªÌ«O°··~°È¬°4%

Àq§J©ó19¥@¬ö¥½´N¶}©l±q¨Æ©ó¹ï¤¤°êªº¶T©ö¬¡°Ê¡A¦V¤¤°ê¾P°â°ª¯Â«×¤Æ¾Ç¸Õ¾¯¡A¨Ã©ó1933¦~¦b¤W®ü¦¨¥ß¤F²Ä¤@®a¤¤°ê¤l¤½¥q¡C2013¦~¡AÀq§Jªï¨Ó¦bµØ¤K¤Q©P¦~¡C

2014¦~9¤ë23¤éÀq§J¶°¹Î¡]Merck KGaA¡^¥¸¸ê170»õ¬ü¤¸²{ª÷¦¬Áʬü°ê¤½¥qSigma-Aldrich Corp[2]¡C

2018¦~4¤ë19¤éÄ_¼ä¥H¬ù34»õ¼Úù(¬ù42»õ¬ü¤¸)ªº²{ª÷»ù®æ¡A¦¬Áʼw°ê[url=]Àq§J¶°¹Î[/url](Merck)ªº¥þ²y®ø¶OªÌ«O°··~°È¡C


https://en.wikipedia.org/wiki/Merck_Group

The Merck Group, branded and commonly known as Merck, is a German multinationalpharmaceutical, chemical and life sciences company headquartered in Darmstadt, with around 50,000 employees in around 70 countries. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies in the world.[7][8]

Merck operates in Europe, Africa, Asia, Oceania and the Americas. It has major research and development centres in Darmstadt, Boston, Tokyo and Beijing. Merck pioneered the commercial manufacture of morphine in the 19th century and for a time held a virtual monopoly on cocaine.

Merck was privately owned until going public on the Frankfurt Stock Exchange in 1995, and is listed on the DAX index of Germany's top companies. The Merck family still controls a majority 70.3% of the company's shares. The Merck Group includes around 250 companies in 180 countries; the current main parent company of the group, since 1995, is named Merck KGaA, and is itself mainly owned by the former main parent company, E. Merck oHG, which now operates as a holding company.

The American pharmaceutical company Merck & Co. was established as a subsidiary of Merck in 1891, but was nationalized by the United States in 1917, before being privatized again when George W. Merck purchased back the stock in 1919.[9] It is known as MSD (Merck Sharp and Dohme) outside of North America. The original Merck of Darmstadt holds the rights to the name Merck in all countries except the U.S. and Canada, where it is known as EMD (Emanuel Merck, Darmstadt). In 2015 Merck adopted a new uniform brand identity for all its subsidiaries, and the company has stressed its intention to protect the brand of "the real Merck" globally and initiated litigation against its former subsidiary over use of the name.[10]



¼w°êÀq§J¶°¹Î

¤½¥qÃþ«¬¦¨¥ß³Ð¿ì¤H¥Nªí¤Hª«Á`³¡²£·~²£«~Àç·~ÃBµ|«e¬Õ¾lµ|«á¬Õ¾lÁ`¸ê²£¸ê²£²b­È­û¤u¤H¼Æºô¯¸
¤W¥«¤½¥q ¼w°êµù¥U (FWB: MRK)
1668¦~
¥±¨½¼w¨½§Æ ¶®¦U Àq§J
¥dº¸-§J¹p (CEO¤Î¸³¨Æ§½¥D®u), «Â·G ¿ü©i´Ë (²z¨Æ·|¥D®u)
¼w°ê¹F©i¬I¶ð¯S
¤Æ¤u, »sÃÄ
²G´¹, ¥Í©R¬ì¾Ç¤Î¤Æ¾Ç©Ê¯à, «D³B¤èÃÄ, ¤p¥÷¤l¤Î ¥Íª«»sÃÄ
£á9.291 billion (2010)[1]
£á1.113 billion (2010)[1]
£á632.1 million (2010)[1]
£á22.39 billion (end 2010)[1]
£á10.37 billion (end 2010)[1]
38000 (end 2012)[1]
www.merck-china.com

Merck KGaA



Type
Traded asIndustryFoundedFounderHeadquartersArea served
Key people
ProductsRevenueNet income
Total assetsNumber of employees
ParentWebsite




Current Merck logo, introduced in 2015.
Publicly traded KGaA
FWB: MRK
Chemicals
pharmaceuticals
1668; 350 years ago
Friedrich Jacob Merck
Darmstadt, Germany
Worldwide
Stefan Oschmann (CEO and Chairman of the executive board), Wolfgang Büchele (Chairman of the supervisory board)
Liquid crystals, life science and performance chemicals, over-the-counter medicines, small molecules and biopharmaceuticals
£á15.024 billion (2016)[1]
£á1.629 billion (2016)[1]
$42.13 billion (2016)[2]
Ca. 50,000 (2016)[3]
E. Merck KG
(70.3% of capital)[4][5][6]
www.merckgroup.com
³»³¡
kaka
¦P¾Ç




UID 6717
ºëµØ 0
¿n¤À 0
©«¤l 6266
¾\ŪÅv­­ 99
µù¥U 2014-5-7
¥Î¤áµù¥U¤Ñ¼Æ 3614
¥Î¤á¥¢ÂÜ¤Ñ¼Æ 1720

120.107.160.32
µoªí©ó 2018-10-28 16:33  ¸ê®Æ ¨p¤H°T®§ 
AstraZeneca plc ªü´µ¯S±¶§Q±d (­^ªÑ AZN)     »sÃÄ

https://www.astrazeneca.com/

https://zh.wikipedia.org/wiki/%E9%98%BF%E6%96%AF%E5%88%A9%E5%BA%B7%E5%88%B6%E8%8D%AF

ªü´µ¯S±¶§Q±d»sÃĤ½¥q¡]­^»y¡GAstraZeneca plc.¡^¡A¬O¤@®a¥Ñ·ç¨åªü´µ¯S©Ô¤½¥q¡]Astra AB¡^©M­^°ê±¶§Q±d¤½¥q¡]Zeneca Group PLC¡^©ó1999¦~4¤ë6¤é¦X¨Ö¦Ó¦¨ªº¤j«¬­^·ç¦X¸ê»sÃÄ¥ø·~¡C­^°ê±¶§Q±d¤½¥q¡A1993¦~³Q°µ¬°«Ò°ê¤Æ¾Ç¤u·~¤½¥q¤@³¡¤À¦Ó¤À©î¥X¨Ó¡Cªü´µ¯S±¶§Q±d¤½¥q¬ãµo¡B»s³y¤Î¾P°â¥Î©óªvÀø®ø¤Æ¡B¤ß¦åºÞ¡B¸~½F¡B¤¤¼Ï¯«¸g¡B©I§l¨t²Î¯e¯f¥H¤Î¥Î©ó³Â¾KªºÃĪ«¡C

¤½¥q¶°¹ÎÁ`³¡¦ì©ó­^°êªº­Û´°¡A¦Ó¬ãµoÁ`³¡«h¦ì©ó·ç¨åªº´µ¼w­ôº¸¼¯¬Ùªº«n®õ§Q­C¡C¥¦¬O´I®É100«ü¼Æ¦¨¤À¡A2014¦~8¤ë1¤é¥H548»õ¥«­È¦¨¬°­Û´°ÃÒ¨é¥æ©ö©Ò¤W¥«ªº²Ä¤»¤j¤½¥q¡C[3]

2015¦~12¤ë16¤éªü´µ§Q±d(AstraZeneca)¥¸¸ê5.75»õ¬ü¤¸¦¬Áʤ饻ªZ¥ÐÃÄ«~(Takeda Pharmaceutical)ªº®Ö¤ß©I§lÃÄ«~·~°È¡A¥]¬A¥i¹w¨¾ºC©Êªý¶ë©ÊªÍ¯f(COPD)ªºÃÄ«~¡A¦b¬ü³c°âªºÃÄ«~¦W¬° Daliresp¡A¦b¼Ú¬w«hºÙ¬° Daxas¡CDaliresp ¤D COPD ¥«³õ­º­Ó¤]¬O°ß¤@¤@­Ó¿ï¾Ü©ÊÁC»Ä¤Gà­酶-4§í¨î¾¯¡C

2015¦~12¤ë17¤éªü´µ§Q±d(AstraZeneca)¥¸¸ê40»õ¬ü¤¸¦¬ÁÊ¥¼¤W¥«¥Íª«»sÃÄ¥ø·~Acerta Pharmaªº55%Åv¯q¡A¥H«KÀò±o«áªÌªº¤@ºØªvÀø¥Õ¦å¯fªº·sÃĪ«¡C


https://en.wikipedia.org/wiki/AstraZeneca

AstraZeneca plc[4] is an Anglo¡VSwedish multinational pharmaceutical and biopharmaceutical company. In 2013, it moved its headquarters to Cambridge, UK, and concentrated its R&D in three sites: Cambridge; Gaithersburg, Maryland, USA (location of MedImmune) for work on biopharmaceuticals; and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs.[5] AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.[6]
The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group[7][8] (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).

AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on the New York Stock Exchange and the OMX exchange.


AstraZeneca plc


Type
Traded asIndustryPredecessorFoundedHeadquartersArea served
Key people
ProductsRevenueOperating income
Net income
Number of employees
SubsidiariesWebsite
Public limited company
LSE: AZN
Nasdaq Stockholm: AZN
FTSE 100 Component
Pharmaceutical
Biotechnology
Astra AB
Zeneca Group plc
6 April 1999; 19 years ago
Cambridge, England[1]
Global
Leif Johansson(Chairman)
Pascal Soriot (CEO)
Pharmaceutical products
US$22.465 billion (2017)[2]
US$3.677 billion (2017)[2]
US$2.868 billion (2017)[2]
59,700 (2017)[3]
MedImmune
www.astrazeneca.com

AstraZeneca plc¤½¥qÃþ«¬ªÑ²¼¥N¸¹¤½¥q«e¨­¦¨¥ß¥Nªí¤Hª«Á`³¡·~°È½d³ò²£·~²£«~Àç·~ÃBµ|«e¬Õ¾lµ|«á¬Õ¾l­û¤u¤H¼Æ¥D­n¤l¤½¥qºô¯¸
¤½¦@¦³­­¤½¥q
LSE¡GAZN
OMX: AZN
NYSE¡GAZN
Astra AB
Zeneca Group plc
1999¦~4¤ë6¤é
Leif Johansson ¡]¸³¨Æªø¡^
Pascal Soriot ¡]CEO¡^
­^°ê­Û´°
¥þ²y
»sÃÄ¡B¥Íª«§Þ³N
ÃĪ«
US$260.95»õ¡]2014¡^[1]
US$21.37»õ¡]2014¡^[1]
US$12.35»õ¡]2014¡^[1]
50,000¡]2014¡^[2]
MedImmune
www.astrazeneca.com
³»³¡